As seen on:
X
LOADING

Here is what our readers say:

"Thanks for your ideas and advice over the last few years" D.M.
"You are one of the most interesting, talented writers I know" A.G.
"I look forward to your emails. They are among the very few that pass my screen." J.C.
"The world needs more of voices like yours" B.W.
"I don't know anyone else that writes like you, shares market points of view like you, and makes things seem personal and approachable!" J.C.
"Thanks for your ideas and advice over the last few years." D.M.

Love Serenades and New Flings

By Vitaliy Katsenelson I sang love serenades for Abbott Labs’ (ABT) stock for a long time. Call me materialistic, but my love for stocks is not ‘til death do us part,’ it is conditional of fundamentals staying intact and of valuation – it has to be undervalued. Abbott Labs’ fundamentals have improved over the last couple […]

Some Thoughts On JNJ and Abbott Labs

It seems that 2007 should be a brighter year for Johnson & Johnson (NYSE JNJ).  In 2006 the company faced major drug expirations which dampened revenue growth. I really like the Pfizer’s (PFE) consumer business acquisition. Despite having a fairly good product line, Pfizer Inc was a pharmaceutical company that happened to have consumer products which came […]

Abbott or GE – who is smarter?

I am not a buyer of Abbott Labs(ABT) at this price, as the margin of safety has been depleted by the latest stock appreciation.  But I like its latest transaction with General Electric (NYSE GE). Abbott proved to be a shrewd buyer and seller.  It played Johnson & Johnson (JNJ), Guidant (GDT) and Boston Scientific (BSX) masterfully […]